NFHealthEconomics

• 6th Jan 2026

  Review of “Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review”

• 10th Nov 2025

  Preferences for advanced therapy medicinal products: understanding the published literature on the value of innovative health interventions

• 6th Oct 2025

  Ending the confusion: defining key terms in value assessment

• 29th Sep 2025

  Should uncertainty be considered a value attribute in its own right or as an inherent component of other attributes as part of value assessment frameworks?

• 15th Sep 2025

  Value attributes of advanced therapy medicinal products: a comprehensive literature review

• 23rd Jun 2025

  The value of hope – the case against inclusion in a value assessment framework for advanced therapies 

• 28th Apr 2025

  Challenges and solutions to the sustainability of gene and cell therapies

• 10th Mar 2025

  A Perspective on ‘Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases’

• 7th Feb 2025

  Review of a ‘systematic review of challenges and opportunities in the implementation of managed entry agreements for advanced therapy medicinal products’

• 9th Dec 2024

  Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe

• 30th Sep 2024

  The ISPOR value flower: application to advanced therapy medicinal products

• 2nd Sep 2024

  A case study of the challenges of demonstrating cost-effectiveness in under-served patient populations: lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease

• 19th Jun 2024

  Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review

• 17th Jun 2024

  Identifying value elements of advanced therapy medicinal products: An opportunistic review of stakeholder responses submitted to NICE as part of reimbursement decision making

• 17th Apr 2024

  Value assessment of advanced therapies: improving patient access to innovative treatments

• 28th Feb 2024

  Should the value of advanced therapies fall under a subjective or objective category? Brief philosophical musings. 

• 30th Jan 2024

  Assessing the value of advanced therapies

• 1st Sep 2022

  Key Questions on the Development of Health Economics

• 12th Apr 2022

  Brief considerations on the value assessment of advanced therapy medicinal products

• 5th Sep 2021

  The potential misnomer of health economics and outcomes research